Ebalzotan

Ebalzotan is a serotonin 5-HT1A receptor agonist that was under development by Eisai Co. for the treatment of anxiety and depression. It reached Phase II clinical trials for these indications but was discontinued.

History

Ebalzotan was first developed by the Japanese pharmaceutical company Eisai Co. The drug was designed to act as a serotonin 5-HT1A receptor agonist, a type of drug that has been used in the treatment of various psychiatric and neurological disorders.

Mechanism of Action

Ebalzotan works by binding to and activating the 5-HT1A receptors in the brain. These receptors are a type of G protein-coupled receptor that are activated by the neurotransmitter serotonin. By activating these receptors, ebalzotan can increase the levels of serotonin in the brain, which can help to alleviate symptoms of anxiety and depression.

Clinical Trials

Ebalzotan underwent Phase II clinical trials for the treatment of anxiety and depression. However, the development of the drug was discontinued for unknown reasons.

See Also

• Serotonin
• 5-HT1A receptor
• Eisai Co.
• Anxiety
• Depression
• Phase II clinical trial
• G protein-coupled receptor

Ebalzotan Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski